Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

BSI-045B showed promising results in a Phase 2a trial for atopic dermatitis. Biosion received $40 million upfront fee and 19.9% shares in Aclaris Therapeutics.